HAE is caused by a mutation of the C1-inhibitor gene. Defective or missing C1-inhibitor permits activation of kallikrein, a protease that is responsible for liberating bradykinin from its precursor kininogen. An excess of bradykinin leads to fluid leakage from blood vessels, causing swelling of tissues typical of HAE.Ecallantide suppresses this pathogenetic mechanism by selectively and reversibly inhibiting the activity of plasma kallikrein.
Ecallantide, also known as DX-88, is a potent recombinant protein belonging to the family of kallikrein inhibitors, specifically designed to target plasma kallikrein activity. Structurally, it is a small protein engineered through recombinant DNA technology, offering high specificity and affinity for its enzymatic target. Its unique mechanism of action involves direct and reversible inhibition of plasma kallikrein, a serine protease involved in the generation of bradykinin and the regulation of vascular permeability. Due to its targeted action and recombinant origin, Ecallantide is highly valued in research settings focused on dissecting the roles of kallikrein-kinin systems in various physiological and pathological processes. Researchers often select this inhibitor for its ability to modulate proteolytic cascades, facilitating the exploration of complex biochemical pathways and the development of novel therapeutic strategies. Its stability, ease of formulation, and reproducible activity make it a reliable tool in both in vitro and in vivo experimental models.
Inflammation and Vascular Permeability Research: Ecallantide is widely utilized in studies investigating the molecular mechanisms underlying inflammation and vascular leakage. By selectively inhibiting plasma kallikrein, it enables researchers to dissect the downstream effects of bradykinin generation and its impact on endothelial cell function, tissue edema, and inflammatory mediator release. This application is particularly valuable in experimental models where precise control of the kallikrein-kinin system is necessary to elucidate the contribution of this pathway to acute and chronic inflammatory responses.
Angioedema Pathway Investigation: The use of DX-88 is instrumental in exploring the pathophysiology of angioedema, a condition characterized by episodic swelling due to increased vascular permeability. In laboratory settings, it helps delineate the role of plasma kallikrein in bradykinin-mediated processes, offering insight into the intricate signaling events that lead to tissue swelling. By modulating kallikrein activity, researchers can evaluate the efficacy of novel compounds or genetic modifications aimed at controlling excessive bradykinin formation.
Protease Cascade Mapping: In the context of proteolytic network analysis, Ecallantide serves as a critical tool for mapping the interactions and regulatory checkpoints within the kallikrein-kinin system. Its use in biochemical assays enables the identification of substrate specificity, feedback mechanisms, and the interplay between different proteases. This facilitates the development of mathematical models and predictive algorithms for protease-driven processes, advancing the understanding of homeostatic and pathological proteolysis.
Biomarker Discovery and Validation: Researchers employ this kallikrein inhibitor in biomarker studies to validate the involvement of plasma kallikrein and its downstream products in various disease states. Through selective inhibition, it is possible to correlate changes in proteolytic activity with the appearance or modulation of specific biomarkers, thereby supporting the identification of diagnostic or prognostic indicators. These studies often leverage high-throughput screening platforms and advanced analytical techniques to quantify the impact of kallikrein modulation on biological samples.
Translational Pharmacology and Drug Development: Ecallantide is frequently incorporated into preclinical pharmacology programs aimed at validating plasma kallikrein as a therapeutic target. Its use in animal models and cell-based systems allows for the assessment of safety, efficacy, and mechanistic action of new drug candidates designed to modulate the kallikrein-kinin pathway. By providing a benchmark for comparison, it supports the iterative optimization of small molecules, antibodies, and other biologics targeting this protease, ultimately accelerating the discovery pipeline for future therapies.
In summary, Ecallantide stands out as a versatile and scientifically robust tool for the detailed investigation of plasma kallikrein-related biology. Its applications span inflammation research, angioedema pathway elucidation, protease cascade mapping, biomarker discovery, and translational pharmacology. By enabling precise modulation of kallikrein activity, it empowers researchers to unravel complex physiological mechanisms and drive innovative advances in biochemical and pharmacological sciences.
Ecallantide (Kalbitor [previously, DX-88]; Dyax, Cambridge, MA) is a recombinant protein synthesized in the yeast Pichia pastoris. Ecallantide is a potent and specific inhibitor of plasma kallikrein. In phase 2 trials, symptoms of angioedema improved within 4 hours after treatment with ecallantide.18,21 The Evaluation of DX-88's Effects in Mitigating Angioedema (EDEMA) 3 trial was a randomized, placebo-controlled, phase 3 evaluation of ecallantide for the treatment of acute attacks of angioedema in patients with hereditary angioedema.
Ecallantide for the Treatment of Acute Attacks in Hereditary Angioedema
Hereditary angioedema (HAE) is a rare, debilitating, and potentially fatal disease characterized by acute attacks of swelling that can affect the abdomen/gastrointestinal tract, larynx, face, genitals, and extremities. Ecallantide is a novel plasma kallikrein inhibitor developed for the treatment of acute HAE attacks. Ecallantide provides relief of acute HAE attack symptoms, with rapidity of response commensurate with therapeutic needs for HAE attack locations.
Response time for ecallantide treatment of acute hereditary angioedema attacks
2. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
3. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis
4. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
5. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More